Recently, the evidence from our previous study proved that fenofibrate could repair the disrupted glutamine–glutamate cycle by upregulating glutamine synthetase, while there is currently no fenofibrate treatment of AD in clinical trials (Long et al., 2024). This evidence concerns the gene GLUL and Alzheimer disease.